Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Financing Activities (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Cash from Financing Activities data on record, last reported at $3.7 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 103.82% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $7.0 million, down 89.47%, while the annual FY2025 figure was $7.0 million, 89.47% down from the prior year.
  • Cash from Financing Activities reached $3.7 million in Q4 2025 per ARQT's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $285.0 million in Q3 2022 and bottomed at -$97.4 million in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $37.9 million, with a median of $1.3 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 452263.49% in 2022, then plummeted 198.11% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $72.9 million in 2021, then crashed by 98.68% to $962000.0 in 2022, then soared by 10221.1% to $99.3 million in 2023, then tumbled by 198.11% to -$97.4 million in 2024, then skyrocketed by 103.82% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $3.7 million in Q4 2025, $1.5 million in Q3 2025, and $1.4 million in Q2 2025.